Cargando…

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation

OBJECTIVE: To validate the robust predictive values of tumor vascularity and reactive cutaneous capillary endothelial proliferation (RCCEP) in combination treatment of transarterial chemoembolization (TACE) and camrelizumab for patients with advanced hepatocellular carcinoma (HCC) and then select th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Liang, Liu, Kai-Cai, Lv, Wei-Fu, Xu, Shao-Bao, Lu, Dong, Zhou, Chun-Ze, Cheng, De-Lei, Gao, Zong-Gen, Shi, Chang-Sheng, Su, Ming-Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531610/ https://www.ncbi.nlm.nih.gov/pubmed/36203820 http://dx.doi.org/10.2147/DDDT.S372276

Ejemplares similares

Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation
por: Song, Geng, et al.
Publicado: (2022)

Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports
por: Hui-Mei, Pang, et al.
Publicado: (2023)

Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report
por: Wu, Rui, et al.
Publicado: (2022)

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
por: Wang, Feng, et al.
Publicado: (2020)

Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
por: Ding, Qi, et al.
Publicado: (2023)

Nasal alar metastasis of advanced hepatocellular carcinoma misdiagnosed as reactive cutaneous capillary endothelial proliferation in a patient treated with camrelizumab and apatinib: a case report
por: Liu, Jin, et al.
Publicado: (2023)

A case report of thalidomide in the treatment of camrelizumab-induced reactive cutaneous capillary hyperplasia
por: Fu, Shujuan, et al.
Publicado: (2023)

Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation
por: Liu, Yi, et al.
Publicado: (2023)

Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event
por: Wu, Ping-Shang, et al.
Publicado: (2022)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma
por: Wang, Enxin, et al.
Publicado: (2019)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
por: Li, Xiaomi, et al.
Publicado: (2023)

Cutaneous Hypervascularization Treatment Using Photo-Mediated Ultrasound Therapy
por: Wang, Mingyang, et al.
Publicado: (2023)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma
por: Ogasawara, Sadahisa, et al.
Publicado: (2016)

Non-hypervascular Hypointense Nodules on Hepatocyte Phase Gadoxetic Acid-Enhanced MR Images: Transformation of MR Hepatobiliary Hypointense Nodules into Hypervascular Hepatocellular Carcinomas
por: Cho, Yun Ku, et al.
Publicado: (2018)

The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE
por: Lu, Liang-He, et al.
Publicado: (2021)

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023)

Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma
por: Ma, Rong, et al.
Publicado: (2022)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma
por: Kong, Lingxiang, et al.
Publicado: (2021)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
por: Kim, Jung Hee, et al.
Publicado: (2017)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
por: Féray, Cyrille, et al.
Publicado: (2023)

Irradiation stent with (125)I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial
por: Lu, Jian, et al.
Publicado: (2023)

Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE
por: Jun, Chung Hwan, et al.
Publicado: (2013)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
por: Chen, Li, et al.
Publicado: (2021)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma
por: Wang, Jia-hong, et al.
Publicado: (2017)

Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
por: Ren, Yanqiao, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma
por: Cai, Yeyu, et al.
Publicado: (2018)

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE
por: Huang, Wu-Kui, et al.
Publicado: (2017)

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma
por: Wang, Yujia, et al.
Publicado: (2022)

Predictors of hepatic decompensation after TACE for hepatocellular carcinoma
por: Kohla, Mohamed A S, et al.
Publicado: (2015)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases
por: Vogl, Thomas J., et al.
Publicado: (2022)

Atypical Small Hemangiomas of the Liver: Hypervascular Hemangiomas
por: Nouira, Kais, et al.
Publicado: (2007)

HYPERVASCULAR LIVER LESIONS IN RADIOLOGICALLY NORMAL LIVER
por: AMICO, Enio Campos, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9sbi6qj5u43fclvdca4r40cab8